CA2547922A1 - Particules virales contenant un vecteur derive d'alpha virus et procede de preparation de ladite particule virale - Google Patents
Particules virales contenant un vecteur derive d'alpha virus et procede de preparation de ladite particule virale Download PDFInfo
- Publication number
- CA2547922A1 CA2547922A1 CA002547922A CA2547922A CA2547922A1 CA 2547922 A1 CA2547922 A1 CA 2547922A1 CA 002547922 A CA002547922 A CA 002547922A CA 2547922 A CA2547922 A CA 2547922A CA 2547922 A1 CA2547922 A1 CA 2547922A1
- Authority
- CA
- Canada
- Prior art keywords
- alphavirus
- derived vector
- derived
- viral
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013598 vector Substances 0.000 title claims abstract description 102
- 239000002245 particle Substances 0.000 title claims abstract description 75
- 241000710929 Alphavirus Species 0.000 title claims abstract description 50
- 230000003612 virological effect Effects 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 108700019146 Transgenes Proteins 0.000 claims abstract description 14
- 238000012217 deletion Methods 0.000 claims abstract description 5
- 230000037430 deletion Effects 0.000 claims abstract description 5
- 238000004113 cell culture Methods 0.000 claims abstract 2
- 239000012228 culture supernatant Substances 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 96
- 241000710961 Semliki Forest virus Species 0.000 claims description 69
- 230000001177 retroviral effect Effects 0.000 claims description 26
- 238000001890 transfection Methods 0.000 claims description 24
- 230000014509 gene expression Effects 0.000 claims description 22
- 241001430294 unidentified retrovirus Species 0.000 claims description 10
- 101710172711 Structural protein Proteins 0.000 claims description 7
- 108700004025 env Genes Proteins 0.000 claims description 6
- 101150030339 env gene Proteins 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 101710091045 Envelope protein Proteins 0.000 claims description 4
- 101710188315 Protein X Proteins 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 108700004026 gag Genes Proteins 0.000 claims description 3
- 108700004029 pol Genes Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000003153 stable transfection Methods 0.000 claims description 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 41
- 239000013612 plasmid Substances 0.000 description 23
- 208000015181 infectious disease Diseases 0.000 description 17
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 10
- 108091027544 Subgenomic mRNA Proteins 0.000 description 9
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 108010092160 Dactinomycin Proteins 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 241000714177 Murine leukemia virus Species 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 6
- 229960000640 dactinomycin Drugs 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 102100034349 Integrase Human genes 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 3
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 3
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010061833 Integrases Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101800000514 Non-structural protein 4 Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 101800000980 Protease nsP2 Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 102100038126 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 241000030538 Thecla Species 0.000 description 1
- 102000001999 Transcription Factor Pit-1 Human genes 0.000 description 1
- 108010040742 Transcription Factor Pit-1 Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000006451 grace's insect medium Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6045—RNA rev transcr viruses
- C12N2810/6054—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Particule virale constituée d'éléments structuraux non issus d'un alpha-viru s et contenant un vecteur dérivé d'alpha-virus rendu défectif pour la réplication, par délétion ou remplacement par au moins un transgene, des gèn es structuraux caractérisée en ce que les éléments structuraux de ladite particule ne sont pas codés par le génome du vecteur dérivé d'alpha-virus. procédé de production de ladite particule qui consiste A exprimer en trans, dans une lignée cellulaire, les gènes codant les éléments structuraux non issus de l'alpha-virus et le vecteur dérivé d'alpha-virus pu is à récupérer les particules virales présentes dans le surnageant de la cultur e cellulaire.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0350951A FR2862982B1 (fr) | 2003-12-02 | 2003-12-02 | Particules virales contenant un vecteur derive d'alpha-virus et procede de preparation de ladite particule virale. |
| FR0350951 | 2003-12-02 | ||
| PCT/FR2004/050631 WO2005056805A1 (fr) | 2003-12-02 | 2004-11-30 | Particules virales contenant un vecteur derive d'alpha virus et procede de preparation de ladite particule virale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2547922A1 true CA2547922A1 (fr) | 2005-06-23 |
Family
ID=34566388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002547922A Abandoned CA2547922A1 (fr) | 2003-12-02 | 2004-11-30 | Particules virales contenant un vecteur derive d'alpha virus et procede de preparation de ladite particule virale |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080118956A1 (fr) |
| EP (1) | EP1697529A1 (fr) |
| JP (1) | JP2007512827A (fr) |
| KR (1) | KR20070085044A (fr) |
| CN (1) | CN101006180A (fr) |
| AU (1) | AU2004297379A1 (fr) |
| BR (1) | BRPI0417126A (fr) |
| CA (1) | CA2547922A1 (fr) |
| FR (1) | FR2862982B1 (fr) |
| RU (1) | RU2398875C2 (fr) |
| WO (1) | WO2005056805A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021142366A1 (fr) * | 2020-01-10 | 2021-07-15 | Carogen Corporation | Compositions et méthodes d'utilisation de vésicules pseudo-virales oncolytiques |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9296790B2 (en) | 2008-10-03 | 2016-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for protein delivery |
| US9506041B2 (en) * | 2012-03-26 | 2016-11-29 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Delivery of packaged RNA to mammalian cells |
| SG10201811190SA (en) | 2013-12-16 | 2019-01-30 | Us Health | Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon |
| CN105176936B (zh) * | 2015-10-23 | 2019-01-11 | 中国科学院武汉物理与数学研究所 | 复制耐受型的西门利克森林病毒的亚克隆及制备方法和应用 |
| US11135283B2 (en) | 2015-11-09 | 2021-10-05 | Immune Design Corp. | Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US6489167B1 (en) * | 1996-09-25 | 2002-12-03 | The Government Of The United States As Represented By The Secretary Of The Department Of Human Services | Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic Togavirus vectors |
| FI20020375A (fi) * | 2002-02-27 | 2003-08-28 | Wahlfors | Menetelmä viruksen kaltaisten partikkeleiden (VKP) tuottamiseksi, plasmidikonstrukti sekä menetelmän käytöt |
-
2003
- 2003-12-02 FR FR0350951A patent/FR2862982B1/fr not_active Expired - Fee Related
-
2004
- 2004-11-30 AU AU2004297379A patent/AU2004297379A1/en not_active Abandoned
- 2004-11-30 RU RU2006123079/13A patent/RU2398875C2/ru not_active IP Right Cessation
- 2004-11-30 WO PCT/FR2004/050631 patent/WO2005056805A1/fr active Application Filing
- 2004-11-30 US US10/581,401 patent/US20080118956A1/en not_active Abandoned
- 2004-11-30 BR BRPI0417126-8A patent/BRPI0417126A/pt not_active Application Discontinuation
- 2004-11-30 EP EP04805869A patent/EP1697529A1/fr not_active Withdrawn
- 2004-11-30 KR KR1020067013209A patent/KR20070085044A/ko not_active Application Discontinuation
- 2004-11-30 JP JP2006541991A patent/JP2007512827A/ja active Pending
- 2004-11-30 CA CA002547922A patent/CA2547922A1/fr not_active Abandoned
- 2004-11-30 CN CNA2004800407046A patent/CN101006180A/zh active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021142366A1 (fr) * | 2020-01-10 | 2021-07-15 | Carogen Corporation | Compositions et méthodes d'utilisation de vésicules pseudo-virales oncolytiques |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2398875C2 (ru) | 2010-09-10 |
| BRPI0417126A (pt) | 2007-12-11 |
| FR2862982A1 (fr) | 2005-06-03 |
| CN101006180A (zh) | 2007-07-25 |
| WO2005056805A1 (fr) | 2005-06-23 |
| RU2006123079A (ru) | 2008-01-10 |
| AU2004297379A1 (en) | 2005-06-23 |
| US20080118956A1 (en) | 2008-05-22 |
| KR20070085044A (ko) | 2007-08-27 |
| JP2007512827A (ja) | 2007-05-24 |
| FR2862982B1 (fr) | 2006-04-28 |
| EP1697529A1 (fr) | 2006-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6585237B2 (ja) | 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達 | |
| Frolov et al. | Alphavirus-based expression vectors: strategies and applications. | |
| ES2330202T3 (es) | Sistemas vectores basados en replicones de alfavirus. | |
| CN1989250B (zh) | Tc-83衍生的甲病毒属载体、颗粒和方法 | |
| US6943015B2 (en) | Large scale production of packaged alphavirus replicons | |
| ES2627445T3 (es) | Partículas de vector de lentivirus resistentes a la inactivación por el complemento | |
| US20110229969A1 (en) | Cell Line for Propagation of Highly Attenuated AlphaViruses | |
| Lundstrom | Alphavirus vectors for gene therapy applications | |
| Ruiz-Guillen et al. | Capsid-deficient alphaviruses generate propagative infectious microvesicles at the plasma membrane | |
| US20080118956A1 (en) | Viral Particles Containing An Alphavirus-Derived Vector And Method For Preparing Said Viral Particle | |
| Garoff et al. | Recent advances in gene expression using alphavirus vectors | |
| Lebedeva et al. | Infectious particles derived from Semliki Forest virus vectors encoding murine leukemia virus envelopes | |
| Dorange et al. | Vesicular stomatitis virus glycoprotein: a transducing coat for SFV‐based RNA vectors | |
| Diatta et al. | Semliki Forest virus-derived virus-like particles: characterization of their production and transduction pathways | |
| Aranda et al. | Recent patents on alphavirus protein expression and vector production | |
| Zhu et al. | Glycoprotein is enough for sindbis virus-derived DNA vector to express heterogenous genes | |
| Boorsma et al. | New applications of alphavirus-based expression vectors | |
| EP1590450A2 (fr) | Production de virus recombines pour la fabrication de vaccins | |
| Lundstrom | Novel developments for applications of alphavirus vectors in gene therapy | |
| Zullo | Assessment of the potential of alphaviruses as vectors for gene therapy | |
| KR19990010297A (ko) | 신경세포내 외래 유전자의 전달할 수 있는 재조합 결손 신드비스 바이러스 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20161107 |